The SAS included 241 South Korean patients (placebo, n=65; perampanel, n=176); the FAS included 225 patients (placebo, n=64; perampanel, n=161). Across double-blind studies, median reductions in seizure frequency/28 days (placebo vs perampanel) were 16.1% vs 25.8% (POS), -16.6% vs 55.6% (SGS), and -54.8% vs 72.3% (PGTCS). Corresponding 50% responder rates were 20.0% (n=12/60) vs 32.9% (n=52/158), 20.0% (n=2/10) vs 59.5% (n=25/42), and 0.0% (n=0/4) vs 66.7% (n=2/3) for POS, SGS, and PGTCS, respectively; seizure-freedom rates were 1.7% (n=1/60) vs 1.3% (n=2/158), 10.0% (n=1/10) vs 26.2% (n=11/42), and 0.0% (n=0/3) vs 33.3% (n=1/3), respectively.

Across double-blind studies, TEAEs occurred in 47 (72.3%) placebo-treated and 144 (81.8%) perampanel-treated patients; with perampanel, the most common were dizziness (n=75 [42.6%]) and somnolence (n=42 [23.9%]).

In this post hoc analysis of adjunctive perampanel in South Korean patients with POS, SGS, or PGTCS, efficacy and safety outcomes were generally consistent with the results from the overall patient populations.